NASDAQ
BLU

BELLUS Health Inc.

Biotechnology
Healthcare

Prices are adjusted according to historical splits.

BELLUS Health Inc. Stock Price

Vitals

Today's Low:
$14.74
Today's High:
$14.75
Open Price:
$14.74
52W Low:
$6.38
52W High:
$14.67
Prev. Close:
$14.74
Volume:
3449256

Company Statistics

Market Cap.:
$1.85 billion
Book Value:
2.912
Revenue TTM:
$15000
Operating Margin TTM:
-602046.7%
Gross Profit TTM:
$16000
Profit Margin:
0%
Return on Assets TTM:
-16.7%
Return on Equity TTM:
-26.76%

Company Profile

BELLUS Health Inc. had its IPO on 2008-12-29 under the ticker symbol BLU.

The company operates in the Healthcare sector and Biotechnology industry. BELLUS Health Inc. has a staff strength of 74 employees.

Stock update

Shares of BELLUS Health Inc. opened at $14.74 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $14.74 - $14.75, and closed at $14.74.

This is a 0% increase from the previous day's closing price.

A total volume of 3,449,256 shares were traded at the close of the day’s session.

In the last one week, shares of BELLUS Health Inc. have increased by +0.14%.

BELLUS Health Inc.'s Key Ratios

BELLUS Health Inc. has a market cap of $1.85 billion, indicating a price to book ratio of 3.0161 and a price to sales ratio of 75790.29.

In the last 12-months BELLUS Health Inc.’s revenue was $15000 with a gross profit of $16000 and an EBITDA of $-89987000. The EBITDA ratio measures BELLUS Health Inc.'s overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, BELLUS Health Inc.’s operating margin was -602046.7% while its return on assets stood at -16.7% with a return of equity of -26.76%.

In Q1, BELLUS Health Inc.’s quarterly earnings growth was a positive 0% while revenue growth was a negative 25%.

BELLUS Health Inc.’s PE and PEG Ratio

Forward PE
0
Trailing PE
0
PEG

Its diluted EPS in the last 12-months stands at $-0.73 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into BELLUS Health Inc.’s profitability.

BELLUS Health Inc. stock is trading at a EV to sales ratio of 53625.7024 and a EV to EBITDA ratio of -11.8482. Its price to sales ratio in the trailing 12-months stood at 75790.29.

BELLUS Health Inc. stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets
$379.54 million
Total Liabilities
$9.81 million
Operating Cash Flow
$0
Capital Expenditure
$0
Dividend Payout Ratio
0%

BELLUS Health Inc. ended 2024 with $379.54 million in total assets and $0 in total liabilities. Its intangible assets were valued at $379.54 million while shareholder equity stood at $368.90 million.

BELLUS Health Inc. ended 2024 with $0 in deferred long-term liabilities, $9.81 million in other current liabilities, in common stock, $-666898000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $85.38 million and cash and short-term investments were $0. The company’s total short-term debt was $0 while long-term debt stood at $0.

BELLUS Health Inc.’s total current assets stands at $327.71 million while long-term investments were $0 and short-term investments were $227.61 million. Its net receivables were $990000.00 compared to accounts payable of $9.44 million and inventory worth $0.

In 2024, BELLUS Health Inc.'s operating cash flow was $0 while its capital expenditure stood at $0.

Comparatively, BELLUS Health Inc. paid $0 in dividends in 2024.

Other key metrics

Current Trading Price
$14.74
52-Week High
$14.67
52-Week Low
$6.38
Analyst Target Price
$15.68

BELLUS Health Inc. stock is currently trading at $14.74 per share. It touched a 52-week high of $14.67 and a 52-week low of $14.67. Analysts tracking the stock have a 12-month average target price of $15.68.

Its 50-day moving average was $14.55 and 200-day moving average was $10.13 The short ratio stood at 0.62 indicating a short percent outstanding of 0%.

Around 1026.1% of the company’s stock are held by insiders while 9040.9% are held by institutions.

Frequently Asked Questions About BELLUS Health Inc.

The stock symbol (also called stock or share ticker) of BELLUS Health Inc. is BLU

The IPO of BELLUS Health Inc. took place on 2008-12-29

Similar Industry Stocks (Biotechnology)

Last Price
Chg
Chg%
$5.53
-0.32
-5.47%
$275.47
-5.15
-1.84%
$446.05
-13.55
-2.95%
$1.8
-0.18
-9.09%
$18.91
0
0%
$8.22
0
0%
$50.25
0.26
+0.52%
$23.42
0.59
+2.58%
$684.45
-16.95
-2.42%

Most Active

Last Price
Chg
Chg%
Amyris Inc (AMRS)
$0.14
0.07
+100%
$0.12
0.04
+45.29%
$0.96
0.05
+5.4%
$1.34
-0.35
-20.71%
Humbl Inc (HMBL)
$0
0
0%

Top Gainers

Last Price
Chg
Chg%
$0
0
+172200%
$0
0
+51200%
$283
280.03
+9428.62%
$11.2
10.57
+1667.68%
Latch Inc (LTCHW)
$0.01
-0.03
+1550%

Top Losers

Last Price
Chg
Chg%
$0.19
-123.15
-99.85%
$0
-0.11
-99.55%
$0
-0
-97.96%
$0
-0.01
-93.94%
$0.01
-0.06
-92.24%

About

BELLUS Health Inc., a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of refractory chronic cough (RCC) and other cough hypersensitivity indications. Its lead product candidate includes BLU-5937, an antagonist of the P2X3 receptor, which is in Phase II clinical trial for treatment of RCC and chronic pruritus. BELLUS Health Inc. was incorporated in 1993 and is based in Laval, Canada.

Address

275 Armand-Frappier Boulevard, Laval, QC, Canada, H7V 4A7